Pancreatic Cancer Therapeutics
SKU
MRR-4342CA32667F
Region
Global
Publication Date
November 2023
Delivery
Immediate
2022
USD 4.25 billion
2030
USD 9.09 billion
2023
USD 4.67 billion
CAGR
9.93%
Pancreatic Cancer Therapeutics Market by Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), Product (Chemotherapy, Gene Therapy, Immunotherapy), End-Use - Global Forecast 2023-2030

[195 Pages Report] The Pancreatic Cancer Therapeutics Market size was estimated at USD 4.25 billion in 2022 and expected to reach USD 4.67 billion in 2023, at a CAGR 9.93% to reach USD 9.09 billion by 2030.

Pancreatic Cancer Therapeutics Market
To learn more about this report, request a free sample copy

Pancreatic cancer therapeutics encompass a variety of treatment modalities used to manage and combat pancreatic cancer, known for its aggressive nature and challenging prognosis. The therapeutic landscape for this malignancy includes surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and supportive care measures that aim to relieve symptoms and improve the quality of life for patients. The need for pancreatic cancer therapeutics is driven by the increasing prevalence of the disease, attributed to factors such as aging populations, lifestyle-related risk factors, and genetic predispositions. Additionally, supportive government policies to expand access to affordable pancreatic cancer treatment have extended the scope and reach of the therapeutic options for patients. However, the complex reimbursement landscape and the inability of clinical trials to provide beneficial and credible results pose concerns about the accuracy and efficacy of the therapies. Moreover, there has been some significant progress in understanding the biology of the disease, resulting in the development of targeted therapeutics and personalized medicine approaches. These treatments are designed to interfere with specific pathways or mechanisms that promote the growth and spread of pancreatic cancer cells.

Pancreatic Cancer Therapeutics Market - Global Forecast 2023-2030
To learn more about this report, request a free sample copy
Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer

Pancreatic neuroendocrine tumors (NETs), also called endocrine pancreatic cancer or islet cell tumors, are a type of cancer associated with the rapid and abnormal growth of endocrine cells, called islet cells, in the pancreas. Treatment for this type of cancer usually involves surgery to remove the tumor cells or the major parts of the body and tail of the pancreas. Furthermore, for tumors that cannot be removed by surgery, treatment may include a combination of chemotherapy or hormone therapy. Exocrine pancreatic cancer, or adenocarcinoma, refers to cancers that form in the tissue of the pancreas, within the ducts that carry pancreatic juices and aid digestion. However, compared to endocrine pancreatic cancers, exocrine pancreatic cancers advance rapidly.

Product: Expanding number of approvals for chemotherapy treatment options

Chemotherapy remains an essential pillar in the treatment of pancreatic cancer, involving systemic drug administration to impede cancer cell proliferation. These cytotoxic medications can be taken orally or injected, and their inability to distinguish between malignant and normal cells results in side effects. However, chemotherapy is a critical component of the therapeutic regimen, employed alongside other strategies to enhance patient outcomes. Gene therapy represents a cutting-edge technique, delivering new genetic material into patients' cells to rectify defective genes responsible for cancer growth or to introduce genes that trigger an immune response against tumor cells. Presently, gene therapy for pancreatic cancer is largely exploratory and confined to clinical research, holding the promise of more precise, individualized treatments in the future. Immunotherapy is a rapidly evolving field that leverages the body's immune defenses against cancer. Pancreatic cancer treatments, including checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapies, are scrutinized for their ability to target cancer cells effectively. The efficacy of immunotherapy in pancreatic cancer varies. However, ongoing investigations are assessing its potential, especially for patients with specific genetic markers. Radiation therapy, a technique employing high-energy particles to eradicate cancer cells, can serve as a solitary treatment or in combination with surgical interventions to manage pancreatic cancer. Technological advancements such as stereotactic body radiation therapy (SBRT) enhance the accuracy of radiation delivery, minimizing collateral damage to healthy tissues. Surgery is the preferred approach for early-stage pancreatic cancer, aiming to excise the tumor completely. Various surgical techniques, such as the Whipple procedure or distal pancreatectomy, are determined by the tumor's pancreatic location. The viability of surgery depends on the cancer's stage and the patient's health status, and it is typically augmented by chemotherapy and radiation to optimize results. Targeted therapy offers a more nuanced attack on cancer by pinpointing and inhibiting specific molecular abnormalities or pathways involved in tumor progression.

End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment

Clinics provide personalized care with a focus on chemotherapy and patient follow-up. However, hospitals are at the core of providing comprehensive care for pancreatic cancer patients as they provide advanced surgery procedures and post-operative care facilities. They are pivotal in conducting major surgical procedures such as Whipple procedures, which are essential for treating operable pancreatic cancer. Research and academic institutions collaborate with biopharmaceutical companies to develop and test new treatments. Furthermore, they provide a foundation for evidence-based practice and contribute to the overall understanding of disease management, which can translate into improved drugs and care strategies.

Regional Insights

The Americas region, particularly the United States and Canada, is characterized by the presence of a robust clinical pipeline, high healthcare expenditure, and several major pharmaceutical companies. Food and Drug Administration (FDA) has approved designations such as Fast Track, Breakthrough Therapy, and Orphan Drug to several pancreatic cancer drugs, which accelerates the regulatory approval process. European nations such as Germany, France, and the United Kingdom are characterized by the presence of heightened healthcare spending, advanced healthcare facilities, and favorable reimbursement policies. The European Medicines Agency (EMA) plays a pivotal role in endorsing new therapeutic options, positively impacting market growth. Strong research collaborations between private and public entities drive innovation in cancer therapeutic research. In APAC countries such as China, Japan, India, and South Korea, there is a growing patient population and increasing awareness regarding cancer diseases, driving the need for therapeutic options. The increase in local generic drug production in countries such as India contributes to regional market dynamics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pancreatic Cancer Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pancreatic Cancer Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients

    Trishula Therapeutics, Inc., a clinical-stage biotechnology company, revealed the initiation of a randomized Phase 2 trial to assess the efficacy and safety of TTX-030, an anti-CD39 antibody, for the treatment of metastatic pancreatic ductal adenocarcinoma patients. This trial is expected to evaluate the combination of TTX-030 with chemotherapy, either with or without budigalimab (an investigational anti-PD-1 antibody), as a first-line treatment option. The study aims to enroll approximately 180 patients worldwide and will primarily focus on assessing progression-free survival in a biomarker-enriched population. [Published On: 2023-11-09]

  • Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy

    Lisata Therapeutics was granted orphan drug designation from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products for LSTA1, an investigational drug specifically designed to treat pancreatic cancer. LSTA1 aims to activate a novel uptake pathway, allowing co-administered or tethered anti-cancer drugs to penetrate solid tumors effectively. Non-clinical data collected by Lisata and its partners demonstrates the enhanced delivery of established and emerging cancer treatments, including immunotherapy, chemotherapy, and RNA-based therapies. [Published On: 2023-10-18]

  • PanCAN Announces New & Advanced Research Investment

    PanCAN committed an unprecedented USD 34 million to its research endeavors, and the funding facilitated the awarding of nine coveted research grants. The research grants emphasize the organization's role as a driving force for progress within the pancreatic cancer sphere, nurturing brilliant scientists proposing cutting-edge research and fostering mentorship for upcoming talent. This impressive array of grants underscores PanCAN's commitment to driving critical advanements and supporting innovative research to defeat pancreatic cancer. [Published On: 2023-08-29]

Key Company Profiles

The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Pancreatic Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Endocrine Pancreatic Cancer
    • Exocrine Pancreatic Cancer
  • Product
    • Chemotherapy
    • Gene Therapy
    • Immunotherapy
    • Radiation Therapy
    • Surgery
    • Targeted Therapy
  • End-Use
    • Cancer Centers/Clinics
    • Hospitals
    • Research Institutes

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Pancreatic Cancer Therapeutics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pancreatic Cancer Therapeutics Market?
  3. What are the technology trends and regulatory frameworks in the Pancreatic Cancer Therapeutics Market?
  4. What is the market share of the leading vendors in the Pancreatic Cancer Therapeutics Market?
  5. Which modes and strategic moves are suitable for entering the Pancreatic Cancer Therapeutics Market?

  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & CoveragePANCREATIC CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
    3. Years Considered for the Study
    4. Currency & PricingUNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
    5. Language
    6. Limitations
    7. Assumptions
    8. Stakeholders
  2. Research Methodology
    1. PANCREATIC CANCER THERAPEUTICS MARKET RESEARCH PROCESS
    2. Define: Research Objective
    3. Determine: Research Design
    4. Prepare: Research Instrument
    5. Collect: Data Source
    6. Analyze: Data Interpretation
    7. Formulate: Data Verification
    8. Publish: Research Report
    9. Repeat: Report Update
  3. Executive Summary
    1. PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2022 VS 2030
  4. Market Overview
    1. IntroductionPANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
    2. Pancreatic Cancer Therapeutics Market, by RegionPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  5. Market Insights
    1. Market DynamicsPANCREATIC CANCER THERAPEUTICS MARKET DYNAMICS
      1. Drivers
        1. Rising prevalence of pancreatic cancer cases across the world
        2. Government initiatives to expand access to pancreatic cancer treatment options
      2. Restraints
        1. Adverse drug recalls and difficulty in availing reimbursement options
      3. Opportunities
        1. Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
        2. Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
      4. Challenges
        1. Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals
    2. Market Segmentation Analysis
      1. Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
      2. Product: Expanding number of approvals for chemotherapy treatment options
      3. End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
    3. Market Trend Analysis
      1. Advancements in pancreatic cancer therapeutics in Americas region due to strong presence of key players and supportive regulatory landscape
      2. Collaborative R&D activities by cancer research organization and improved support for clinical trials of novel therapies to elevate the advancements in pancreatic cancer therapeutics in the Asia-Pacific
      3. Concerted efforts of researchers, funding agencies, and regulatory bodies catalyzing to delivering novel pancreatic cancer therapeutic solutions across EMEA
    4. Cumulative Impact of High Inflation
    5. Porter’s Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    6. Value Chain & Critical Path Analysis
    7. Regulatory Framework
  6. Pancreatic Cancer Therapeutics Market, by Type
    1. IntroductionPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
    2. Endocrine Pancreatic CancerPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY ENDOCRINE PANCREATIC CANCER, BY , 2018-2030 (USD MILLION)
    3. Exocrine Pancreatic CancerPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY EXOCRINE PANCREATIC CANCER, BY , 2018-2030 (USD MILLION)
  7. Pancreatic Cancer Therapeutics Market, by Product
    1. IntroductionPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
    2. ChemotherapyPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY , 2018-2030 (USD MILLION)
    3. Gene TherapyPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY , 2018-2030 (USD MILLION)
    4. ImmunotherapyPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY , 2018-2030 (USD MILLION)
    5. Radiation TherapyPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY , 2018-2030 (USD MILLION)
    6. SurgeryPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY , 2018-2030 (USD MILLION)
    7. Targeted TherapyPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY , 2018-2030 (USD MILLION)
  8. Pancreatic Cancer Therapeutics Market, by End-Use
    1. IntroductionPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2022 VS 2030 (%)PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2022 VS 2023 VS 2030 (USD MILLION)PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    2. Cancer Centers/ClinicsPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS/CLINICS, BY , 2018-2030 (USD MILLION)
    3. HospitalsPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY , 2018-2030 (USD MILLION)
    4. Research InstitutesPANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY , 2018-2030 (USD MILLION)
  9. Americas Pancreatic Cancer Therapeutics Market
    1. Introduction
    2. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    3. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Argentina
    5. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    6. Brazil
    7. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    8. Canada
    9. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    10. Mexico
    11. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    12. United States
    13. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    14. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  10. Asia-Pacific Pancreatic Cancer Therapeutics Market
    1. Introduction
    2. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    3. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Australia
    5. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    6. China
    7. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    8. India
    9. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    10. Indonesia
    11. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    12. Japan
    13. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    14. Malaysia
    15. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    16. Philippines
    17. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    18. Singapore
    19. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    20. South Korea
    21. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    22. Taiwan
    23. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    24. Thailand
    25. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    26. Vietnam
    27. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  11. Europe, Middle East & Africa Pancreatic Cancer Therapeutics Market
    1. Introduction
    2. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    3. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Denmark
    5. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    6. Egypt
    7. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    8. Finland
    9. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    10. France
    11. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    12. Germany
    13. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    14. Israel
    15. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    16. Italy
    17. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    18. Netherlands
    19. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    20. Nigeria
    21. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    22. Norway
    23. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    24. Poland
    25. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    26. Qatar
    27. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    28. Russia
    29. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    30. Saudi Arabia
    31. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    32. South Africa
    33. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    34. Spain
    35. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    36. Sweden
    37. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    38. Switzerland
    39. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    40. Turkey
    41. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    42. United Arab Emirates
    43. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
    44. United Kingdom
    45. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  12. Competitive Landscape
    1. FPNV Positioning MatrixPANCREATIC CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022PANCREATIC CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
    2. Market Share Analysis, By Key PlayerPANCREATIC CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022PANCREATIC CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
    3. Competitive Scenario Analysis, By Key Player
      1. Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
      2. Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy
      3. PanCAN Announces New & Advanced Research Investment
      4. Prestige Biopharma and Imagion Biosystems Sign Partnership Agreement to Develop Early Pancreatic Cancer Diagnosis Platform
      5. TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
      6. Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
      7. Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
      8. FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer
      9. FDA Clears TME Pharma’s IND for Pancreatic Cancer Therapy Trial
      10. GenesisCare Launches ViewRay MRIdian MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center
      11. USD 3 Million National Grant to Fund Pancreatic Cancer Study
      12. Leap Therapeutics Acquires Flame Biosciences
      13. Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
      14. Faeth Therapeutics Raises USD 47 million to Advance Clinical Trials for Cancer
      15. AstraZeneca-Merck's Lynparza Wins EU Approval for Pancreatic Cancer
  13. Competitive Portfolio
    1. Key Company Profiles
      1. Abbvie Inc.
      2. Amgen Inc.
      3. Ascentage Pharma Group
      4. Astellas Pharma Inc.
      5. AstraZeneca PLC
      6. Bristol-Myers Squibb Company
      7. C.H. Boehringer Sohn AG & Co. KG
      8. Carl Zeiss AG
      9. Carrick Therapeutics Limited
      10. Cipla Limited
      11. Dr. Reddy’s Laboratories Ltd.
      12. Eli Lilly and Company
      13. F. Hoffmann-La Roche AG
      14. Faeth Therapeutics, Inc.
      15. FUJIFILM Holdings Corporation
      16. GE HealthCare Technologies, Inc.
      17. GenesisCare
      18. GlaxoSmithKline PLC
      19. Hetero Healthcare Limited
      20. ImmunityBio, Inc.
      21. Innovent Biologics Inc.
      22. Johnson & Johnson Services, Inc.
      23. Lupin Limited
      24. Merck & Co., Inc.
      25. Mitsubishi Heavy Industries, Ltd.
      26. NGM Biopharmaceuticals, Inc.
      27. NovalGen
      28. Novartis AG
      29. PanTher Therapeutics, Inc.
      30. Pfizer, Inc.
      31. RenovoRx, Inc.
      32. Sun Pharmaceutical Industries Ltd.
      33. Teva Pharmaceutical Industries Ltd.
      34. Zentalis Pharmaceuticals, Inc.
    2. Key Product Portfolio
  1. Abbvie Inc.
  2. Amgen Inc.
  3. Ascentage Pharma Group
  4. Astellas Pharma Inc.
  5. AstraZeneca PLC
  6. Bristol-Myers Squibb Company
  7. C.H. Boehringer Sohn AG & Co. KG
  8. Carl Zeiss AG
  9. Carrick Therapeutics Limited
  10. Cipla Limited
  11. Dr. Reddy’s Laboratories Ltd.
  12. Eli Lilly and Company
  13. F. Hoffmann-La Roche AG
  14. Faeth Therapeutics, Inc.
  15. FUJIFILM Holdings Corporation
  16. GE HealthCare Technologies, Inc.
  17. GenesisCare
  18. GlaxoSmithKline PLC
  19. Hetero Healthcare Limited
  20. ImmunityBio, Inc.
  21. Innovent Biologics Inc.
  22. Johnson & Johnson Services, Inc.
  23. Lupin Limited
  24. Merck & Co., Inc.
  25. Mitsubishi Heavy Industries, Ltd.
  26. NGM Biopharmaceuticals, Inc.
  27. NovalGen
  28. Novartis AG
  29. PanTher Therapeutics, Inc.
  30. Pfizer, Inc.
  31. RenovoRx, Inc.
  32. Sun Pharmaceutical Industries Ltd.
  33. Teva Pharmaceutical Industries Ltd.
  34. Zentalis Pharmaceuticals, Inc.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Pancreatic Cancer Therapeutics Market
The Global Pancreatic Cancer Therapeutics Market size was estimated at USD 4.25 billion in 2022 and expected to reach USD 4.67 billion in 2023.
The Global Pancreatic Cancer Therapeutics Market to grow USD 9.09 billion by 2030, at a CAGR of 9.93%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.